Inventiva Future Growth

Future criteria checks 3/6

Inventiva is forecast to grow earnings and revenue by 61.3% and 53.2% per annum respectively. EPS is expected to grow by 38.3% per annum. Return on equity is forecast to be 40% in 3 years.

Key information

61.3%

Earnings growth rate

38.26%

EPS growth rate

Biotechs earnings growth	27.8%
Revenue growth rate	53.2%
Future return on equity	39.98%
Analyst coverage	Good
Last updated	13 Aug 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Aug 05

Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives

Summary Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR agonist, lanifibranor. Lanifibranor's potential lies in combination therapy, offering dual metabolic and anti-fibrotic benefits independent of weight loss, complementing GLP-1 and SGLT2 agents. Inventiva has secured sufficient liquidity through Q2 2027, with contingent access to further capital, and has strengthened governance ahead of the pivotal NATiV3 Phase 3 readout. NATiV3 results in Q4 2026 are the defining catalyst; success could secure lanifibranor a differentiated and versatile role in the evolving MASH treatment landscape. Read the full article on Seeking Alpha

Seeking Alpha • Jul 08

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Summary Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was conducted, and it was noted that the phase 3 NATiV3 study should continue without modification. The global non-alcoholic steatohepatitis market is expected to reach $48.3 billion by the end of 2035. It could compete against other MASH companies with the use of lanifibranor by establishing several competitive advantages or by combining it with GLP-1 drugs. Read the full article on Seeking Alpha

Seeking Alpha • Feb 22

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Summary Enrollment pause in phase III NATiV3 study, using lanifibranor for the treatment of patients with NASH, only expected to last 4 to 6 weeks; Trial to continue on with protocol amendments. Publication of results from phase IIa LEGEND study, using lanifibranor in combination with Jardiance for the treatment of patients with NASH and Type 2 Diabetes, expected Q1 of 2024. The global non-alcoholic steatohepatitis treatment market size is expected to reach $48.3 billion by the end of 2035. Several competitors in NASH, but the company might overcome most with the fact that oral administration can be given; Another option to beat the competition would be through combination treatments such as lanifibranor + Jardiance. Read the full article on Seeking Alpha

Seeking Alpha • Sep 21

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

France-based clinical-stage biopharma Inventiva (NASDAQ:IVA) on Wednesday said it had entered into a licensing and collaboration agreement with a unit of Chinese pharmaceutical group Sino Biopharm for its non-alcoholic steatohepatitis (NASH) treatment lanifibranor. As per the deal, Inventiva (IVA) will get a $12M upfront payment along with $5M in short term potential milestone payments. IVA will also be eligible to get up to $290M in clinical, regulatory and commercial milestone payments, in addition to tiered royalties. Sino Biopharm will oversee the development and commercialization of lanifibranor in Greater China, IVA said in a statement. IVA's lanifibranor had previously received a breakthrough therapy designation from the U.S. FDA. U.S.-listed shares of IVA -2.8% to $3.82 after hours.

Earnings and Revenue Growth Forecasts

NasdaqGM:IVA - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	214	-37	-42	34	11
12/31/2027	108	-103	170	103	12
12/31/2026	7	-152	-82	-116	12
12/31/2025	7	-354	-105	-105	N/A
9/30/2025	12	-333	-98	-98	N/A
6/30/2025	17	-311	-91	-91	N/A
3/31/2025	16	-248	-89	-89	N/A
12/31/2024	14	-184	-86	-86	N/A
9/30/2024	17	-144	-86	-85	N/A
6/30/2024	19	-104	-85	-85	N/A
3/31/2024	21	-107	-84	-83	N/A
12/31/2023	23	-110	-82	-82	N/A
9/30/2023	22	-95	-73	-73	N/A
6/30/2023	22	-80	-64	-64	N/A
3/31/2023	20	-67	-55	-54	N/A
12/31/2022	18	-54	-45	-45	N/A
9/30/2022	14	-55	-50	-49	N/A
6/30/2022	10	-56	-55	-54	N/A
3/31/2022	10	-56	-54	-53	N/A
12/31/2021	9	-50	-48	-48	N/A
9/30/2021	7	-45	-46	-45	N/A
6/30/2021	6	-41	-44	-43	N/A
3/31/2021	5	-36	-35	-35	N/A
12/31/2020	5	-34	-31	-31	N/A
9/30/2020	7	-29	-24	-24	N/A
6/30/2020	10	-25	-17	-17	N/A
3/31/2020	10	-27	-23	-23	N/A
12/31/2019	11	-30	-29	-28	N/A
9/30/2019	9	-34	N/A	-33	N/A
6/30/2019	7	-37	N/A	-38	N/A
3/31/2019	8	-35	N/A	-35	N/A
12/31/2018	7	-33	N/A	-34	N/A
9/30/2018	8	-29	N/A	-27	N/A
6/30/2018	9	-25	N/A	-21	N/A
3/31/2018	9	-22	N/A	-19	N/A
12/31/2017	10	-19	N/A	-17	N/A
9/30/2017	11	-16	N/A	-18	N/A
6/30/2017	13	-13	N/A	-19	N/A
3/31/2017	14	-10	N/A	-17	N/A
12/31/2016	14	-7	N/A	-15	N/A
9/30/2016	13	-8	N/A	-14	N/A
6/30/2016	12	-8	N/A	-13	N/A
3/31/2016	10	-9	N/A	-13	N/A
12/31/2015	9	-9	N/A	-14	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IVA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IVA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IVA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IVA's revenue (53.2% per year) is forecast to grow faster than the US market (12.9% per year).

High Growth Revenue: IVA's revenue (53.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IVA's Return on Equity is forecast to be high in 3 years time (40%)

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/23 06:32
End of Day Share Price	2026/08/21 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inventiva S.A. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Eliana Merle	Barclays
Edward Nash	Canaccord Genuity
Prakhar Agrawal	Cantor Fitzgerald & Co.

Inventiva Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Recent updates

Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.

Inventiva S.A. announced that it expects to receive €130 million in funding from BlackRock, Inc., Claret Capital Partners Limited

Inventiva S.A., Annual General Meeting, Jun 30, 2026

Inventiva Announces Executives Changes

Inventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million.

Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million.

Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million.

Inventiva Announces CEO Changes

Inventiva Announces Executive Appointments

Inventiva Announces the Publication in Journal of Hepatology Reports on Results of Lanifibranor Treatment on Liver Sinusoidal Endothelial Cells in Patients with MASLD/MASH and in Preclinical Models of the Disease

Inventiva Announces the Appointment of Renée Aguiar-Lucander to Its Board of Directors

Inventiva Announces the Publication in Clinical Gastroenterology and Hepatology of Its Analysis of New Biomarker Signatures Predictive of Histological Response in Patients with Mash Treated with Lanifibranor

Inventiva S.A., Annual General Meeting, May 22, 2025

Inventiva S.A. and Hepalys Pharma, Inc. Announce the Initiation of the Clinical Development Program of Lanifibranor in Japan

Inventiva S.A. to Report First Half, 2025 Results on Sep 25, 2025

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis